

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE

99 AUG 15 PM 12: 53

LOBBYING REPORT H.D.

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Abbott Laboratories			
2. Address <input type="checkbox"/> Check if different than previously reported 1710 Rhode Island Ave., NW, Suite 300, Washington, DC 20036			
3. Principal Place of Business (if different from line 2) City: Abbott Park State/Zip (or Country) Illinois 60064			
4. Contact Name Cynthia B. Sensibaugh	Telephone (202) 659-8524	E-mail (optional)	5. Senate ID # 66-12
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID #

TYPE OF REPORT 8. Year 1999 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇒ Termination Date _____

11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13	
<p align="center">12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ <small>Income (nearest \$20,000)</small></p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center">13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ <u>1.25</u> million <small>Expenses (nearest \$20,000)</small></p> <p>14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input checked="" type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature _____

Printed Name and Title _____

Registrant Name Abbott Laboratories Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific lobbying issues

Labor/WHS FY2000 Appropriations - funding for state AIDS Drug Assistance programs under the Ryan White Act.

17. House(s) of Congress and Federal agencies contacted Check if None

House
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Rosemary T. Haas (Abbott Laboratories, Inc.)		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date _____

Printed Name and Title _____

Registrant Name Abbott Laboratories Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CON (one per page)

16. Specific lobbying issues

- 1. H.R. 1875 - Interstate Class Action Jurisdiction Act
- 2. S. 353 - Class Action Fairness Act

17. House(s) of Congress and Federal agencies contacted Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Cynthia E. Sensibaugh (Abbott Laboratories, Inc.)		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date _____

Printed Name and Title _____

Registrant Name Abbott Laboratories Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

1. H.R. 2100 - Anti-tampering Act of 1999
2. Proposal to amend the Drug Price Competition and Patent Term Restoration Act of 1994

17. House(s) of Congress and Federal agencies contacted

Check if None

House
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (If applicable)	New
Cynthia B. Sensibaugh (Abbott Laboratories, Inc.)		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature _____ Date _____

Printed Name and Title _____

Registrant Name Abbott Laboratories Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code LBR (one per page)

16. Specific lobbying issues

1. H.R. 987 - Workplace Preservation Act
2. H.R. 1439 - Safety and Health Audit Promotion and Whistleblower Improvement Act of 1999
3. H.R. 775, S. 96 - Y2K Act, Limits liability of manufacturers for good faith efforts to remediate Y2K problems.

17. House(s) of Congress and Federal agencies contacted Check if None

House
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Cynthia B. Sensibaugh (Abbott Laboratories, Inc.)		<input type="checkbox"/>
Rosemary T. Haas (Abbott Laboratories, Inc.)		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date _____

Printed Name and Title _____

Registrant Name Abbott Laboratories Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

- 1. S. 6, S. 1344 - Patients' Bill of Rights
- 2. S. 1243 - Prostate Cancer Research and Prevention Act

17. House(s) of Congress and Federal agencies contacted Check if None

House
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
David W. Landsidle (Abbott Laboratories, Inc.)		<input type="checkbox"/>
Cynthia B. Sensibaugh (Abbott Laboratories, Inc.)		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date _____

Printed Name and Title _____

Registrant Name Abbott Laboratories Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MM (one per page)

16. Specific lobbying issues

1. H.R. 664, S. 731 - Prescription Drug Fairness for Seniors Act of 1999
2. H.R. 1495, S. 841 - Access to Rx Medications in Medicare Act of 1999
3. H.R. 2030 - Medicare Patient Access to Technology Act of 1999
4. HCFA's "inherent reasonableness" proposal to lower Medicare reimbursement for blood glucose test strips and enteral nutrition.

17. House(s) of Congress and Federal agencies contacted

Check if None

House
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
David W. Landside (Abbott Laboratories, Inc.)		<input type="checkbox"/>
Cynthia B. Sensibaugh (Abbott Laboratories, Inc.)		<input type="checkbox"/>
Rosemary T. Haas (Abbott Laboratories, Inc.)		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature _____ Date _____

Printed Name and Title _____

Registrant Name Abbott Laboratories Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code 2201 (cont'd) (one per page)

16. Specific lobbying issues

- 5. H.R. 1090 - Medicare Full Access to Cancer Treatment Act
- 6. H.R. 2241 - Hospital Outpatient Preservation Act
- 7. Administration's FY2000 budget proposal - provisions relating to Medicare:
 - a) reimbursement of prescription drugs
 - b) reduction in laboratory fee schedule

17. House(s) of Congress and Federal agencies contacted Check if None
House _____
Senate _____

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
David W. Landsidle (Abbott Laboratories, Inc.)		<input type="checkbox"/>
Cynthia B. Sensibaugh (Abbott Laboratories, Inc.)		<input type="checkbox"/>
Rosemary T. Haas (Abbott Laboratories, Inc.)		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date _____

Printed Name and Title _____

Registrant Name Abbott Laboratories Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific lobbying issues

1. H.R. 835, S. 680 - permanent extension of the Research and Development Tax Credit
2. H.R. 2488 - Financial Freedom Act of 1999
3. S. 1429 - Taxpayer Refund Act of 1999
4. European Union proposal to eliminate the foreign sales corporation

17. House(s) of Congress and Federal agencies contacted

Check if None

House
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
David W. Landsidle (Abbott Laboratories, Inc.)		<input type="checkbox"/>
Cynthia B. Sensibaugh (Abbott Laboratories, Inc.)		<input type="checkbox"/>
Rosemary T. Haas (Abbott Laboratories, Inc.)		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature Cynthia B. Sensibaugh Date August 16, 1999

Printed Name and Title Cynthia B. Sensibaugh, Director, Washington Affairs